ArticleInfection and immunity2009
Human microbiota-secreted factors inhibit shiga toxin synthesis by enterohemorrhagic Escherichia coli O157:H7.
Article in Infection and immunity, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 107 citations in OpenAlex.
- Clinical Efficacy of Probiotics for Allergic Rhinitis: Results of an Exploratory Randomized Controlled Trial.Nutrients · 2024Trial
- Article
- Comparative genomics and transcriptomics of theResearch square · 2025Article
- Intestinal dysbiosis associated with non-nutritive sweeteners intake: an effect without a cause?Frontiers in nutrition · 2025Review
- Review
- Crosstalk between Gut Microbiota and Host Immunity: Impact on Inflammation and Immunotherapy.Biomedicines · 2023Review
- Signals triggering prophage induction in the gut microbiota.Molecular microbiology · 2022Review
- Mcc1229, an Stx2a-Amplifying Microcin, Is ProducedInfection and immunity · 2022Article
- ABToxins · 2022Review
- Bacteria from gut microbiota associated with diarrheal infections in children promote virulence of Shiga toxin-producing and enteroaggregativeFrontiers in cellular and infection microbiology · 2022Article
- Review
- A Toxic Environment: a Growing Understanding of How Microbial Communities Affect Escherichia coli O157:H7 Shiga Toxin Expression.Applied and environmental microbiology · 2020Review
- Metagenomic growth rate inferences of strains in situ.Science advances · 2020Article
- Identification of Antibiotics That Diminish Disease in a Murine Model of Enterohemorrhagic Escherichia coli Infection.Antimicrobial agents and chemotherapy · 2020Article
- A Putative Microcin Amplifies Shiga Toxin 2a Production of Escherichia coli O157:H7.Journal of bacteriology · 2019Article
- Inhibition of enterohemorrhagicBiomedical reports · 2019Article
- Divergent Influence to a Pathogen Invader by Resident Bacteria with Different Social Interactions.Microbial ecology · 2019Article
- Microbiota-Immune Interaction in the Pathogenesis of Gut-Derived Infection.Frontiers in immunology · 2019Review
- Prophage induction, but not production of phage particles, is required for lethal disease in a microbiome-replete murine model of enterohemorrhagic E. coli infection.PLoS pathogens · 2019Article
- Modulation of EnterohaemorrhagicMicroorganisms · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escherichia coli O157:H7 is a food-borne pathogen causing hemorrhagic colitis and hemolytic-uremic syndrome, especially in children. The main virulence factor responsible for the more serious disease is the Shiga toxin 2 (Stx2), which is released in the gut after oral ingestion of the organism. Although it is accepted that the amount of Stx2 produced by E. coli O157:H7 in the gut is critical for the development of disease, the eukaryotic or prokaryotic gut factors that modulate Stx2 synthesis are largely unknown. In this study, we examined the influence of prokaryotic molecules released by a complex human microbiota on Stx2 synthesis by E. coli O157:H7. Stx2 synthesis was assessed after growth of E. coli O157:H7 in cecal contents of gnotobiotic rats colonized with human microbiota or in conditioned medium having supported the growth of complex human microbiota. Extracellular prokaryotic molecules produced by the commensal microbiota repress stx(2) mRNA expression and Stx2 production by inhibiting the spontaneous and induced lytic cycle mediated by RecA. These molecules, with a molecular mass of below 3 kDa, are produced in part by Bacteroides thetaiotaomicron, a predominant species of the normal human intestinal microbiota. The microbiota-induced stx(2) repression is independent of the known quorum-sensing pathways described in E. coli O157:H7 involving SdiA, QseA, QseC, or autoinducer 3. Our findings demonstrate for the first time the regulatory activity of a soluble factor produced by the complex human digestive microbiota on a bacterial virulence factor in a physiologically relevant context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.